Adaptimmune Company
Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.
Investors
Technology:
CAR-T
Industry:
PharmTech
Headquarters:
Oxton, York, United Kingdom
Founded Date:
2008-01-01
Employees Number:
251-500
Funding Status:
IPO
Investors Number:
16
Total Funding:
254000000
Estimated Revenue:
$1M to $10M
Last Funding Date:
2021-09-07
Last Funding Type:
Post-IPO Equity
Register and Claim Ownership